PE/Cyanine5.5 Anti-Mouse CD274/PD-L1 Antibody[10F.9G2]

Introducing the PE/Cyanine5.5 Anti-Mouse CD274/PD-L1 Antibody [10F.9G2], a highly advanced and meticulously crafted product designed to revolutionize the field of immunology research. This antibody, meticulously developed using cutting-edge technology, offers unparalleled specificity and sensitivity in detecting and analyzing CD274/PD-L1 expression in mouse samples.

With its exceptional performance, this antibody enables researchers to delve deeper into the intricate mechanisms of immune regulation and gain valuable insights into the role of CD274/PD-L1 in various physiological and pathological processes. Its unique formulation, incorporating the powerful PE/Cyanine5.5 fluorochrome, ensures optimal signal detection and minimal background noise, guaranteeing accurate and reliable results.

The PE/Cyanine5.5 Anti-Mouse CD274/PD-L1 Antibody [10F.9G2] boasts an impressive array of features that set it apart from conventional antibodies. Its high affinity and specificity for CD274/PD-L1 make it an indispensable tool for flow cytometry, immunofluorescence, and immunohistochemistry applications. Furthermore, its exceptional stability and consistency ensure consistent performance across multiple experiments, eliminating any concerns of batch-to-batch variability.

This antibody is meticulously manufactured under stringent quality control measures, adhering to the highest industry standards. Each batch undergoes rigorous testing to ensure purity, potency, and functionality, guaranteeing optimal performance and reproducibility. Its compatibility with various sample types, including cell lines, tissues, and biological fluids, further enhances its versatility and applicability in diverse research settings.

In summary, the PE/Cyanine5.5 Anti-Mouse CD274/PD-L1 Antibody [10F.9G2] represents a groundbreaking advancement in immunology research. Its exceptional specificity, sensitivity, and reliability make it an indispensable tool for scientists and researchers seeking to unravel the complexities of CD274/PD-L1 biology. With this antibody, the boundaries of knowledge in immunology are poised to be pushed further, opening new avenues for therapeutic interventions and improved patient outcomes.